Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;40(6):629-635.
doi: 10.1007/s00292-019-00675-w.

[The 2019 FIGO classification for cervical carcinoma-what's new?]

[Article in German]
Affiliations
Review

[The 2019 FIGO classification for cervical carcinoma-what's new?]

[Article in German]
L-C Horn et al. Pathologe. 2019 Nov.

Abstract

Numerous therapeutic and prognostic studies of cervical carcinoma have necessitated a revision of the FIGO classification.For microinvasive carcinomas, the horizontal dimension is no longer considered and diagnosis and staging will solely be made by the depth of cervical stromal invasion. Lymphovascular invasion beyond the deepest point of stromal infiltration by tumor cells does not alter the stage.There will be a new subclassification of macroinvasive carcinoma confined to the uterine cervix, which will be made by largest tumor extension as follows: FIGO IB1/T1b1 - invasive carcinoma >0.5 cm depth of stromal invasion and ≤2 cm in largest dimension, FIGO IBII/T1b2: - invasive carcinoma >2 cm and ≤4 cm, FIGO IBII/T1b3 - invasive carcinoma >4 cm. Pelvic as well as para-aortic lymph nodes will be defined as regional nodes. Pelvic lymph node metastases only will be categorised as FIGO IIIC1/pN1a and para-aortic lymph node involvement with or without concomitant pelvic involvement will be FIGO IIIC2/pN1b. Uterine corpus as well as adnexal involvement are not relevant for staging purpose.

Keywords: Cervix and carcinoma; FIGO-classification; Prognosis; Staging; TNM-classification; Tumor size.

PubMed Disclaimer

References

    1. Lancet Oncol. 2016 Jun;17(6):e240-e253 - PubMed
    1. Int J Gynecol Cancer. 2007 May-Jun;17(3):623-8 - PubMed
    1. Gynecol Oncol. 2011 Sep;122(3):491-4 - PubMed
    1. Gynecol Oncol. 2014 Jul;134(1):42-6 - PubMed
    1. Ann Surg Oncol. 2015 Mar;22(3):728-33 - PubMed